Individual Bioequivalence Stricter Standards Suggested By Committee
Executive Summary
FDA will consider making average bioequivalence the only standard for approval of generic products in its revised guidance on bioavailabiltiy and bioequivalence studies
You may also be interested in...
Bioequivalence For Modified-Release Drugs Will Need Non-Replicate Studies
FDA's revised bioavailability/bioequivalence guidance recommends non-replicate study designs for modified-release dosage forms
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials